1
|
Nilasaroya A, Kop AM, Collier RC, Kennedy B, Kelsey LJ, Pollard F, Ha JF, Morrison DA. Establishing local manufacture of PPE for healthcare workers in the time of a global pandemic. Heliyon 2023; 9:e13349. [PMID: 36816240 PMCID: PMC9922675 DOI: 10.1016/j.heliyon.2023.e13349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2022] [Revised: 01/10/2023] [Accepted: 01/25/2023] [Indexed: 02/16/2023] Open
Abstract
A face shield is a secondary personal protective equipment (PPE) for healthcare workers (HCW). Worn with the appropriate face masks/respirators, it provides short term barrier protection against potentially infectious droplet particles. Coronavirus disease 2019 (COVID-19) caused a spike in demand for PPE, leading to a shortage and risking the safety of HCW. Transport restrictions further challenged the existing PPE supply chain which has been reliant on overseas-based manufacturers. Despite the urgency in demand, PPE must be properly tested for functionality and quality. We describe the establishment of local face shields manufacture in Western Australia to ensure adequate PPE for HCW. Ten thousand face shields for general use (standard) and for ear, nose and throat (ENT) specialist use were produced. Materials and design considerations are described, and the face shields were vigorously tested to the relevant Standards to ensure their effectiveness as a protective barrier, including splash and impact resistance. Comparative testing with traditional and other novel face shields was also undertaken. Therapeutic Goods Administration (TGA) licence was obtained to manufacture and supply the face shields as a Class I medical device. The swiftness of process is a credit to collaboration from industry, academia and healthcare.
Collapse
Affiliation(s)
- Anastasia Nilasaroya
- Centre for Implant Technology and Retrievals Analysis (CITRA), Department of Medical Engineering and Physics, Royal Perth Hospital, Perth, Western Australia, 6000, Australia
| | - Alan Matthew Kop
- Centre for Implant Technology and Retrievals Analysis (CITRA), Department of Medical Engineering and Physics, Royal Perth Hospital, Perth, Western Australia, 6000, Australia
| | - Ryan Christopher Collier
- Centre for Implant Technology and Retrievals Analysis (CITRA), Department of Medical Engineering and Physics, Royal Perth Hospital, Perth, Western Australia, 6000, Australia
| | - Brendan Kennedy
- BRITElab, Harry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands, Western Australia, 6009, Australia and Centre for Medical Research, The University of Western Australia, Crawley, Western Australia, 6009, Australia,Department of Electrical, Electronic & Computer Engineering, School of Engineering, The University of Western Australia, 35 Stirling Highway, Perth, Western Australia, 6009, Australia,Australian Research Council Centre for Personalised Therapeutics Technologies, Australia
| | - Lachlan James Kelsey
- Vascular Engineering Laboratory, Harry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands and Centre for Medical Research, The University of Western Australia, Crawley, Western Australia, 6009, Australia,Department of Mechanical Engineering, School of Engineering, The University of Western Australia, 35 Stirling Highway, Perth, Western Australia, 6009, Australia
| | - Faz Pollard
- Adarsh Australia, 6 Crocker Drive, Malaga, Western Australia, 6090, Australia
| | - Jennifer Fong Ha
- Department of Paediatrics Otolaryngology Head & Neck Surgery, Perth Children's Hospital, 15 Hospital Avenue, Nedlands, Western Australia, 6009, Australia,Murdoch ENT, Wexford Medical Centre, Suite 17-18, Level 1, 3 Barry Marshall Parade, Murdoch, Western Australia, 6150, Australia,Department of Surgery, The University of Western Australia, Stirling Highway, Nedlands, Western Australia, 6009, Australia
| | - David Anthony Morrison
- Centre for Implant Technology and Retrievals Analysis (CITRA), Department of Medical Engineering and Physics, Royal Perth Hospital, Perth, Western Australia, 6000, Australia,Corresponding author.
| |
Collapse
|
2
|
Tay T, Agius C, Hamilton R, Bodle J, Rockman S. Investigation into alternative testing methodologies for characterization of influenza virus vaccine. Hum Vaccin Immunother 2016; 11:1673-84. [PMID: 26090618 PMCID: PMC4514297 DOI: 10.1080/21645515.2015.1034914] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
The objective of this study was to explore various testing methodologies suitable for characterizing sedimented or agglomerated material. To model this, bioCSL's split influenza virus vaccine, Fluvax® was utilized. The investigation was conducted on 5 dispensed lots of commercially manufactured vaccine, formulated for the 2013 Southern Hemisphere season. Vaccine syringes were initially inspected by visual tests; the material was then aseptically pooled for characterization assessment by microscopy and several agglomeration assays. All syringes passed bioCSL's description test where any fine or large sized particles of sediment observed in the vaccine were resuspended upon shaking; inverted light microscopy verified that the sediment morphology was consistent with influenza vaccine. Electron microscopic examination of pooled vaccine material demonstrated the presence of typical influenza structures including split virus, virosomes, whole virus particles and agglomerates. An optical density turbidity assay revealed relatively high protein recoveries in the vaccine supernatant post-centrifugation treatment, thus indicative of a well-dispersed vaccine formulation. This was corroborated by particle sizing analysis using dynamic light scattering which generated reproducible volume particle size distributions of a polydisperse nature. Ultraviolet-visible absorbance profiles further confirmed the presence of some agglomerated material. Data from all methods demonstrated consistent results between all batches of vaccine. Therefore, this investigation revealed the suitability and usefulness of the various methodologies in characterizing the appearance of agglomerated vaccine material. It is suggested that such methods may be applicable and beneficial for the development of a wider spectrum of heterogeneous and agglomerated formulations to provide safe, efficacious and superior quality biopharmaceutical products.
Collapse
Key Words
- AI, Agglomeration index
- ANOVA, Analysis of variance
- AUC, Analytical ultracentrifugation
- DLS, Dynamic light scattering
- EM, Electron microscopy
- EP, European Pharmacopoeia
- FDA, Food and Drug Administration
- FFF, Field flow fractionation
- HA, Hemagglutinin
- ILM, Inverted light microscopy
- IVV, Influenza virus vaccine
- NA, Neuraminidase
- OD, Optical density
- ODT, Optical density turbidity
- PSD, Particle size distribution
- QbD, Quality by Design
- RCF, Relative centrifugal force
- RI, Refractive index
- SEC, Size exclusion chromatography
- SH, Southern Hemisphere
- SLS, Static light scattering
- TEM, Transmission electron microscope
- TGA, Therapeutic Goods Administration
- TIV, Trivalent influenza vaccine
- UV, Ultraviolet
- biopharmaceuticals
- characterization methods
- dispersed formulation
- influenza vaccine
- protein agglomeration
- sedimentation
Collapse
Affiliation(s)
- Tracy Tay
- a Influenza Research and Development; bioCSL Pty Ltd. ; Parkville , Victoria , Australia
| | | | | | | | | |
Collapse
|